CTLA4 and neoplasm: The ICI drugs are designed to block PD1/PD-L1 or CTLA4/B7 pathway interaction, relieving the inhibitory effects on T cells, allowing re-activation, proliferation and differentiation of T cells, enhancing the immune function and anti-tumor response.